offspring of DFM-accompanied pregnancies, and those who were not. A Kaplan-Meyer survival curve was used to assess cumulative hospitalization incidence. A Cox proportional hazards model was used to control for baseline selected confounders. RESULTS: 439 (0.18%) of 242,342 included deliveries were accompanied by complaint of DFM. Total neurological-related hospitalization rate and hospitalizations due to movement disorders, were higher among the exposed group (4.8% vs. 3.1%; OR¼1.57, 95% CI 1.01-2.43; p¼0.044; and 3.2% vs. 1.8%; OR¼1.76, 95% CI 1.02-3.0; p¼0.036, respectively; Table) . Likewise, higher cumulative incidence of neurological-related hospitalizations was observed using a Kaplan-Meyer survival curve (log rank p-value ¼ 0.019; Figure) . This association between DFM and increased long-term neurological morbidity remained significant in the COX proportional hazards model controlling for gestational age (adjusted HR ¼ 1.58; 95% CI 1.03e2.43, p¼0.036).
OBJECTIVE:
To determine if pregnant women with Opioid Use Disorder (OUD) enrolled in a comprehensive multidimensional program, The Perinatal Assistance and Treatment Home (PATHways) program, had improved neonatal outcomes compared to stable opioid dependent pregnant women delivered prior to the inception of the program STUDY DESIGN: This was a retrospective case control study. Women diagnosed with OUD enrolled in PATHways program between 2014 and 2016, stable on Opioid Maintenance Therapy (OMT) with buprenorphine were eligible. Control population included pregnant women with OUD on buprenorphine, delivered at our institution within two years prior to the inception of the program. PATHways program involves group prenatal care with a structured patient education on neonatal abstinence syndrome (NAS) reduction and relapse prevention, weekly substance abuse counseling, peer support and consultation with MFM, addiction medicine and neonatology providers. The primary outcome was a composite of five neonatal outcomes including pharmacologically treated NAS, hospital stay >5days, Finnegan score >8, neonatal intensive care unit (NICU) admissions, or small for gestational age (SGA) infants. Several other secondary outcomes were analyzed. All infants were monitored for a minimum of 5 days after birth for NAS. Statistical analysis included t-test, chi square and Fischer's exact test where appropriate RESULTS: Seventy-four (74) patients in the PATHways group were compared with 54 patients in the control group. Demographic characteristics were similar. PATHways patients were significantly less likely to experience the composite outcome than the control group (77% vs 94.4%, P¼0.007). PATHways group compared to controls significantly less frequently required morphine for NAS (23% vs. 44.4%, P¼0.01) and hospital stay > 5days (58.1% vs. 92.6%, P<0.0001) ( Table 1) . Pathways group compared to controls had significantly shorter hospital stay (11 AE 9.9 days vs. 15 AE 10.9 days, P¼0.048), were on significantly lower buprenorphine dose (12 AE 5 mg vs. 16 AE 6 mg, P¼ 0.005) and required significantly less morphine (0.09 AE 0.1 mg/kg/dose vs. 0.16 AE 0.06 mg/kg/dose, P¼0.004) ( was included; women with pre-existing psychiatric conditions were excluded. ICD-9-CM diagnosis codes identified birth type and psychiatric conditions from 9 months prior (for exclusion) to delivery until one year after delivery. The primary outcome was presentation to the ED or hospital within one year of delivery for management of severe psychiatric morbidity, measured via a composite including: suicide attempt, depression, anxiety, posttraumatic stress disorder (PTSD), acute stress reaction, or adjustment disorder. Secondary outcomes included individual measures of the composite and a substance use composite (drug or alcohol use or dependence). We compared outcomes after stillbirth !23 weeks to those after term, liveborn singletons using multivariable logistic regression to adjust for mode of delivery and maternal age, race, health insurance type, and income quartile. RESULTS: 8245 women with stillbirth and 1,207,280 with term, singleton livebirth were included. Within one year of stillbirth, 3.4% of women had severe psychiatric morbidity: the odds were 2.5 times higher compared to those with livebirth (adjusted odds ratio (aOR) 2.5 (95% confidence interval (CI) 2.22 e 2.82). With the exception of acute stress reaction, each condition within the psychiatric composite was associated with significantly higher odds of severe psychiatric morbidity in the year after delivery in women with stillbirth compared to livebirth, particularly for adjustment disorder (aOR 4.90 (95%CI 3.40 e 7.08)) and PTSD (aOR 4.31 (95% CI 2.29 e 8.10)). After stillbirth, women also had significantly higher odds of presenting to the ED or hospital for substance use (aOR 2.38 (95% CI 1.95 e 2.91)). CONCLUSION: Delivering a stillbirth is associated with increased risk of severe psychiatric morbidity and substance use in the following year, suggesting women who have a stillbirth may benefit from additional psycho-social support for up to a year after their delivery.
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